MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION
Mitral valve prolapse (MVP) is a manifestation of the hereditary syndrome of differentiated or undifferentiated connective tissue dysplasia (CTD). Genetic defect of synthesis and/or degradation of extracellular matrix is the basis of the CTD. MVP is a frequent manifestation of CTD and often is its t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/967 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227824005644288 |
|---|---|
| author | A. G. Avtandilov K. M. Dzeranova A. A. Pukhaeva E. D. Manizer |
| author_facet | A. G. Avtandilov K. M. Dzeranova A. A. Pukhaeva E. D. Manizer |
| author_sort | A. G. Avtandilov |
| collection | DOAJ |
| description | Mitral valve prolapse (MVP) is a manifestation of the hereditary syndrome of differentiated or undifferentiated connective tissue dysplasia (CTD). Genetic defect of synthesis and/or degradation of extracellular matrix is the basis of the CTD. MVP is a frequent manifestation of CTD and often is its the main manifestation, despite of the involvement of other organs and systems. Micronutrient deficiencies, especially magnesium one is the mostly important in CTD manifestations. Pathogenetic pharmacotherapy should be comprehensive. Magnesium drugs must necessarily be included in the treatment regimen. Analysis of domestic and international study data on magnesium orotate use in patients with MVP is presented. The results of their own experience of the orotate magnesium use and its possible effect on the inotropic cardiac function in patients with MVP are presented. |
| format | Article |
| id | doaj-art-cf406dd2efbb4902a9470504f58527fc |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-cf406dd2efbb4902a9470504f58527fc2025-08-23T10:00:24ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-016567768410.20996/1819-6446-2010-6-5-677-684966MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATIONA. G. Avtandilov0K. M. Dzeranova1A. A. Pukhaeva2E. D. Manizer3Russian Medical Academy for Postgraduate EducationRussian Medical Academy for Postgraduate EducationRussian Medical Academy for Postgraduate EducationMunicipal specialized polyclinic № 156 (Municipal medical center for the youth)Mitral valve prolapse (MVP) is a manifestation of the hereditary syndrome of differentiated or undifferentiated connective tissue dysplasia (CTD). Genetic defect of synthesis and/or degradation of extracellular matrix is the basis of the CTD. MVP is a frequent manifestation of CTD and often is its the main manifestation, despite of the involvement of other organs and systems. Micronutrient deficiencies, especially magnesium one is the mostly important in CTD manifestations. Pathogenetic pharmacotherapy should be comprehensive. Magnesium drugs must necessarily be included in the treatment regimen. Analysis of domestic and international study data on magnesium orotate use in patients with MVP is presented. The results of their own experience of the orotate magnesium use and its possible effect on the inotropic cardiac function in patients with MVP are presented.https://www.rpcardio.online/jour/article/view/967connective tissue dysplasiamitral valve prolapseinotropic heart functionmagnesium orotate |
| spellingShingle | A. G. Avtandilov K. M. Dzeranova A. A. Pukhaeva E. D. Manizer MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION Рациональная фармакотерапия в кардиологии connective tissue dysplasia mitral valve prolapse inotropic heart function magnesium orotate |
| title | MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION |
| title_full | MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION |
| title_fullStr | MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION |
| title_full_unstemmed | MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION |
| title_short | MAGNESIUM AND MITRAL VALVE PROLAPSE. EFFICACY AND THE POINTS OF APPLICATION |
| title_sort | magnesium and mitral valve prolapse efficacy and the points of application |
| topic | connective tissue dysplasia mitral valve prolapse inotropic heart function magnesium orotate |
| url | https://www.rpcardio.online/jour/article/view/967 |
| work_keys_str_mv | AT agavtandilov magnesiumandmitralvalveprolapseefficacyandthepointsofapplication AT kmdzeranova magnesiumandmitralvalveprolapseefficacyandthepointsofapplication AT aapukhaeva magnesiumandmitralvalveprolapseefficacyandthepointsofapplication AT edmanizer magnesiumandmitralvalveprolapseefficacyandthepointsofapplication |